Synthesis and Development of Highly Selective Pyrrolo[2,3-<i>d</i>]pyrimidine CSF1R Inhibitors Targeting the Autoinhibited Form

Thomas Ihle Aarhus(Norwegian University of Science and Technology), Frithjof Bjørnstad(Norwegian University of Science and Technology), Camilla Wolowczyk(Norwegian University of Science and Technology), Kristin Uhlving Larsen, Line Rognstad(Norwegian University of Science and Technology), Trygve Leithaug(Norwegian University of Science and Technology), Anke Unger(Lead Discovery Center (Germany)), Peter Habenberger(Lead Discovery Center (Germany)), Alexander Wolf(Lead Discovery Center (Germany)), Geir Bjørkøy(Norwegian University of Science and Technology), Clare Pridans(Centre for Inflammation Research), Jan Eickhoff(Lead Discovery Center (Germany)), Bert Klebl(Lead Discovery Center (Germany)), Bård Helge Hoff(Norwegian University of Science and Technology), Eirik Sundby(Norwegian University of Science and Technology)
Journal of Medicinal Chemistry
May 16, 2023
Cited by 13Open Access
Full Text

Abstract

Colony-stimulating factor-1 receptor (CSF1R) is a receptor tyrosine kinase that controls the differentiation and maintenance of most tissue-resident macrophages, and the inhibition of CSF1R has been suggested as a possible therapy for a range of human disorders. Herein, we present the synthesis, development, and structure–activity relationship of a series of highly selective pyrrolo[2,3-d]pyrimidines, showing subnanomolar enzymatic inhibition of this receptor and with excellent selectivity toward other kinases in the platelet-derived growth factor receptor (PDGFR) family. The crystal structure of the protein and 23 revealed that the binding conformation of the protein is DFG-out-like. The most promising compounds in this series were profiled for cellular potency and subjected to pharmacokinetic profiling and in vivo stability, indicating that this compound class could be relevant in a potential disease setting. Additionally, these compounds inhibited primarily the autoinhibited form of the receptor, contrasting the behavior of pexidartinib, which could explain the exquisite selectivity of these structures.


Related Papers

No related papers found

Powered by citation graph analysis